Regeneron Pharmaceuticals Inc. buy Cantor Fitzgerald
Summary
This prediction is currently active. The BUY prediction by Cantor_Fitzgerald shows slight gains of 2.12%. A total of €0.94 was paid as dividends for this prediction. This prediction currently runs until 02.02.27. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 3.538% | 3.538% |
| iShares Core DAX® | -0,20 % | 5,47 % |
| iShares Nasdaq 100 | 2,57 % | 10,09 % |
| iShares Nikkei 225® | 0,60 % | 9,87 % |
| iShares S&P 500 | 1,80 % | 7,40 % |
Comments by Cantor_Fitzgerald for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Cantor_Fitzgerald for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
23.04.26
23.04.27
23.04.26
Regeneron Pharmaceuticals Inc.
29.10.25
29.10.26
23.04.26

